These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19909230)

  • 21. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
    Newman-Tancredi A; Rivet JM; Cussac D; Touzard M; Chaput C; Marini L; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):188-99. PubMed ID: 12923612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Cosi C; Waget A; Rollet K; Tesori V; Newman-Tancredi A
    Brain Res; 2005 May; 1043(1-2):32-41. PubMed ID: 15862515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
    Sun H; Zhu L; Yang H; Qian W; Guo L; Zhou S; Gao B; Li Z; Zhou Y; Jiang H; Chen K; Zhen X; Liu H
    Bioorg Med Chem; 2013 Feb; 21(4):856-68. PubMed ID: 23332346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
    Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
    Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Trends in the Treatment of Schizophrenia.
    Meltzer HY
    CNS Neurol Disord Drug Targets; 2017; 16(8):900-906. PubMed ID: 28758583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
    Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
    Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
    Ichikawa J; Meltzer HY
    Brain Res; 2000 Mar; 858(2):252-63. PubMed ID: 10708676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
    Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics.
    Favor DA; Powers JJ; White AD; Fitzgerald LW; Groppi V; Serpa KA
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5666-9. PubMed ID: 20801650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.